

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRINCIPAL OPERATING RESULTS ESTIMATE OF TASLY PHARMACEUTICAL FOR THE YEAR ENDED 31 DECEMBER 2025

On 6 February 2026, Tasly Pharmaceutical released its unaudited preliminary financial information for the year ended 31 December 2025.

Tasly Pharmaceutical Group Co., Ltd. (天士力醫藥集團股份有限公司) (“**Tasly Pharmaceutical**”) is a company incorporated in the People’s Republic of China. The shares of Tasly Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Tasly Pharmaceutical is owned as to approximately 28% equity interest by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”), through its non-wholly-owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd (華潤三九醫藥股份有限公司) (“**CR Sanjiu**”), and is accounted for as a subsidiary of the Company.

On 6 February 2026, Tasly Pharmaceutical released its unaudited preliminary financial information for the year ended 31 December 2025 (the “**Reporting Period**”) (the “**Tasly Pharmaceutical Preliminary Financial Information**”). Set out below are the key financial information of the Tasly Pharmaceutical Preliminary Financial Information:

I. MAJOR FINANCIAL INFORMATION AND INDICATORS FOR THE YEAR OF 2025 (UNAUDITED)

Unit: RMB ten thousand

Item	The Reporting Period	The corresponding period of previous year	Increase/decrease (%)
Total operating revenue	823,647.74	849,814.19	-3.08%
Operating profit	135,041.38	107,592.25	25.51%
Total profit	134,066.12	106,868.98	25.45%
Net profit attributable to the shareholders of the listed company	110,540.33	95,558.62	15.68%
Net profit attributable to the shareholders of the listed company (exclude extraordinary gains or losses)	78,651.50	103,570.63	-24.06%
Basic earnings per share (<i>RMB</i>)	0.74	0.64	15.63%
Weighted average return on net asset (%)	9.07%	7.68%	Increase by 1.39%

Item	As of the end of the Reporting Period	As of the beginning of the Reporting Period	Increase/decrease (%)
Total assets	1,534,169.88	1,497,629.54	2.44%
Equity attributable to the shareholders of the listed company	1,240,151.47	1,190,332.90	4.19%
Share capital	149,395.00	149,395.00	0.00%
Net assets per share attributable to the shareholders of the listed company (<i>RMB</i>)	8.30	7.97	4.14%

Note: The above information for this Reporting Period is based on information from unaudited consolidated financial statements. The financial information set out in the 2025 annual report to be published by Tasly Pharmaceutical shall prevail.

II. DETAILS OF OPERATING RESULTS AND FINANCIAL POSITIONS

In 2025, Tasly Pharmaceutical has become a member of the CR Sanjiu group, entering a new chapter of integrated development driven by innovation, it successfully completed the “100-day integration” with CR Sanjiu and steadily promoted the “first year integration” work, and on the basis of business stability, team stability and customer stability, guided by the “four reshaping”, it accelerated the integration of resources with CR Sanjiu. In the face of policy factors such as centralized procurement cost control in the pharmaceutical industry, Tasly Pharmaceutical continued focus on the three major treatment areas of cardiovascular and metabolism, neuro/psychiatry, and digestion, actively promoted its core business, comprehensively improved enterprise efficiency and competitiveness, adhered to driving innovation, achieved high-quality development, and steadily moved towards the goal of “becoming a leading enterprise in China’s pharmaceutical market”.

During the Reporting Period, Tasly Pharmaceutical achieved total operating revenue of RMB8.236 billion, representing a year-on-year decrease of 3.08% and achieved a net profit attributable to shareholders of the listed company of RMB1.105 billion, representing a year-on-year increase of 15.68%. In terms of the magnitude of change, the year-on-year decrease in operating revenue was mainly due to Tasly Pharmaceutical’s pharmaceutical commercial income (mainly the chain pharmacy business) being affected by industry policies such as “outpatient coordination”, resulting in a 14.24% year-on-year decrease.

The Tasly Pharmaceutical Preliminary Financial Information have been prepared in accordance with the PRC Generally Accepted Accounting Principles and are unaudited. The final audited results for the Reporting Period to be disclosed by Tasly Pharmaceutical in its 2025 annual report shall prevail.

The financial information is limited to Tasly Pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the Tasly Pharmaceutical audited annual financial results, please refer to the annual report for the year ended 31 December 2025 to be published by Tasly Pharmaceutical on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 6 February 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.